(Total Views: 523)
Posted On: 10/02/2024 5:38:47 PM
Post# of 155816
mAb's in LL-PLS publication.
Not like for like per say, but it's what was mentioned & can be data "compared", as development of LL-PLS continues.
LL-PLS pub excerpt:
"Supporting this notion, subcutaneous administration of broadly neutralizing Abs, such as VRC01, VRC01-LS, and VRC07-523LS, has been demonstrated to be safe in neonates exposed to HIV.Citation64 "
____
VRC01-LS Ai overview;
VRC01-LS is a long-acting version of the VRC01 monoclonal antibody that targets the CD4-binding site of the HIV-1 envelope glycoprotein
____
VRC07-523LS:
VRC07-523LS is a second-generation bNAb that targets the CD4 binding site on HIV envelope gp120
& that's the only LS mentions.
Our publication took 5 months.
How many months prior to compile/format the data?
Say that because from PLS paper:
" While our study did not directly test protection against viral challenges, CCR5 blockade by leronlimab does not necessitate additional effector or immune components from the host.
Therefore, measuring RO provides a reliable, albeit not exclusive, indirect estimate of its efficacy, especially since our measurements were limited to blood CD4+ T-cells.
Additionally, the fact that leronlimab functions independently of immune effector molecules may confer a distinct advantage over other anti-HIV immunotherapies by not requiring host factors.
This significant difference is especially relevant in immunocompromised and neonate populations with compromised or immature immune systems.
Ultimately, however, we will evaluate the protection of newborns against viral infection afforded by the in-utero leronlimab-PLS transfer in our follow-up study to confirm treatment efficacy."
____
Our follow-up for efficacy is already well under development as of the publication.
Also checked foreign trial sites for anyone trying CCR5 / FcRn/ placenta/ fetus.
None.
LL-PLS has a wide open FcRn route for Cytodyn. Looking forward to the follow-up trial results.
Efficacy of the world's 1st HIV mAb/ CCR5, for mother & fetus.
Not like for like per say, but it's what was mentioned & can be data "compared", as development of LL-PLS continues.
LL-PLS pub excerpt:
"Supporting this notion, subcutaneous administration of broadly neutralizing Abs, such as VRC01, VRC01-LS, and VRC07-523LS, has been demonstrated to be safe in neonates exposed to HIV.Citation64 "
____
VRC01-LS Ai overview;
VRC01-LS is a long-acting version of the VRC01 monoclonal antibody that targets the CD4-binding site of the HIV-1 envelope glycoprotein
____
VRC07-523LS:
VRC07-523LS is a second-generation bNAb that targets the CD4 binding site on HIV envelope gp120
& that's the only LS mentions.
Our publication took 5 months.
How many months prior to compile/format the data?
Say that because from PLS paper:
" While our study did not directly test protection against viral challenges, CCR5 blockade by leronlimab does not necessitate additional effector or immune components from the host.
Therefore, measuring RO provides a reliable, albeit not exclusive, indirect estimate of its efficacy, especially since our measurements were limited to blood CD4+ T-cells.
Additionally, the fact that leronlimab functions independently of immune effector molecules may confer a distinct advantage over other anti-HIV immunotherapies by not requiring host factors.
This significant difference is especially relevant in immunocompromised and neonate populations with compromised or immature immune systems.
Ultimately, however, we will evaluate the protection of newborns against viral infection afforded by the in-utero leronlimab-PLS transfer in our follow-up study to confirm treatment efficacy."
____
Our follow-up for efficacy is already well under development as of the publication.
Also checked foreign trial sites for anyone trying CCR5 / FcRn/ placenta/ fetus.
None.
LL-PLS has a wide open FcRn route for Cytodyn. Looking forward to the follow-up trial results.
Efficacy of the world's 1st HIV mAb/ CCR5, for mother & fetus.
(4)
(0)
